Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.
Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.
Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.
Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.
Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.
Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.
Significant enrichment of CDKN2A/B and cell cycle pathway alterations were observed in patients with non–small cell lung cancer and brain metastases vs extracranial disease, and a higher fraction of the genome was altered in these patients vs matched primary tumor controls.
FOLFOXIRI plus bevacizumab led to a significant improvement in progression-free survival, objective response rate, and R0/1 resections vs FOLFOX/FOLFIRI plus bevacizumab but resulted in increased toxicity in patients with initially unresectable colorectal cancer liver metastases and right-sided and/or RAS- or BRAF V600E–mutated primary tumors.
Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.
The combination of lasofoxifene and abemaciclib provided a meaningful progression-free survival benefit and elicited encouraging responses with an acceptable toxicity profile in patients with locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.
Ribociclib plus an aromatase inhibitor elicited improved symptom-related quality of life outcomes compared with abemaciclib plus an aromatase inhibitor as first-line therapy in postmenopausal patients with hormone receptor–positive, HER2–negative advanced breast cancer, according to findings from a matching-adjusted indirect comparison study.
Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.
Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.
Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.
Bevacizumab combined with first-line chemotherapy was shown to improve progression-free survival and overall survival in patients with advanced ovarian clear cell carcinoma.
Pembrolizumab plus chemotherapy with or without bevacizumab prolonged progression-free survival and overall survival in key subgroups of patients with persistent, recurrent, or metastatic cervical cancer, displaying benefits similar to those seen in the broader patient population.
Patients with metastatic non–small cell lung cancer treated with first-line nivolumab and ipilimumab plus chemotherapy experienced prolonged benefit in overall survival compared with those who received chemotherapy alone.
Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.
Twice-daily oral ruxolitinib plus carboplatin and paclitaxel given as frontline neoadjuvant and post-surgical treatment to patients with stage III or IV ovarian cancer was found to be feasible and to improve progression-free survival compared with chemotherapy alone.
Patritumab deruxtecan exhibited promising clinical activity in heavily pretreated patients with advanced non-small cell lung cancer without EGFR-activating mutations, including activity in patients with other identified driver genomic alterations.
Resection of the primary tumor prior to systemic therapy was not found to extend overall survival in patients with asymptomatic colon and high rectal cancer who had synchronous unresectable metastases.
Higher treatment discontinuation rates with abemaciclib were associated with factors including age of 65 year or older, enrollment in either North America or Europe, an ECOG performance status of 1, postmenopausal status, 1 to 3 positive lymph nodes, and 4 or more preexisting comorbidities in patients with hormone receptor–positive, HER2-negative high-risk early breast cancer.
Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.
Neoadjuvant nivolumab in combination with platinum-based doublet chemotherapy extended event-free survival in patients with stage IB-IIA non–small cell lung cancer who had pathologic complete response, according to a post hoc analysis of the phase 3 CheckMate 816 trial.
The addition of the MET inhibitor capmatinib to pembrolizumab failed to improve clinical outcomes in patients with treatment-naïve non–small cell lung cancer with PD-L1 expression of at least 50% vs pembrolizumab alone, according to an analysis of outcomes of patients in the MET unselected population treated in a phase 2 trial.
Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.
The combination of dabrafenib plus trametinib demonstrated a significant improvement in overall response rate, clinical benefit rate, and progression-free survival and fewer grade 3 or greater adverse effects and discontinuations vs carboplatin and vincristine in pediatric patients with low-grade glioma harboring a BRAF V600 mutation.
Fixed-dose nivolumab plus relatlimab elicited continued progression-free survival benefit vs nivolumab alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial.
Mobocertinib may have limited intracranial activity in patients with EGFR exon 20 insertion–positive, non–small cell lung cancer with brain metastases at baseline, given the numerically lower response rate observed with the agent in this population.
The combination of lurbinectedin and pembrolizumab demonstrated preliminary efficacy signals and was shown to be tolerable with a median relative dose intensity exceeding 90% in patients with small cell lung cancer that relapsed on platinum-based chemotherapy, according to findings from the phase 1/2 LUPER study.
